Funder: Vertex Pharmaceuticals

Due Dates: Rolling (most programs) | RFP window (beta thalassemia & sickle cell disease only)

Funding Amounts: No strict cap; requests should represent fair market value. Up to $750,000 over 3 years for select CF programs; general guidance is not to exceed 30% of an organization’s annual operating budget.

Summary: Supports investigator-sponsored studies, research grants, and sponsorships advancing care and scientific knowledge in cystic fibrosis, pain, IgA nephropathy, and other Vertex focus areas.

Key Information: Requests must be submitted at least 60 days before event start; rolling submissions except for certain RFP-limited areas.